The Global Oncolytic Virus Therapy Market was valued at USD 150.8 Million in 2020 and is expected to witness a growth of 25.28% from 2019-2026 and reach USD 467.7 Million by 2026.
Major players In the Market include Amgen, Oncolytics Biotech, Viralytics, Transgene SA, Oncolys BioPharma, Targovax, PsiOxus Therapeutics, SillaJen Biotherapeutics, Sorrento Therapeutics, Lokon Pharma, Genelux Corporation, Vyriad, TILT Biotherapeutics and Cold Genesys.
April 2020, Amgen announced that data from its oncology pipeline and marketed portfolio will be presented during the ASCO20 Virtual Scientific Program taking place May 29 - 31, 2020. The oncology pipeline includes updated first-in-human studies evaluating sotorasib, a first-in-class investigational KRAS inhibitor, in patients with advanced colorectal cancer (CRC) and other solid tumors. Updated results from a Phase 1 dose escalation study of AMG 330, a BiTE (bispecific T cell engager) molecule, in acute myeloid leukemia will be featured in an oral presentation.
Nov 2020, Oncolytics Biotech Inc. announced positive results from ReoGlio, an investigator-sponsored, phase 1b trial evaluating the combination of pelareorep and granulocyte-macrophage colony-stimulating factor alongside standard chemo radiotherapy and adjuvant temozolomide for the treatment of glioblastoma multiforme (GBM). The results, which were featured in a podium presentation at the 2020 Society of Neuro-Oncology Annual Meeting, show a compelling signal of efficacy and demonstrate the safety and tolerability of the pelareorep-based combination therapy in newly diagnosed GBM patients.
Nov 2020, Transgene, a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, presented new data on BT-001, a novel oncolytic vaccinia virus armed with a Treg-depleting human recombinant anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment, an oncolytic vaccinia virus armed with a Tregdepleting human recombinant anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment.
Dec 2020, Oncolys BioPharma Inc. announced that Oncolys received the upfront payment in accordance with License Agreement with Transposon Therapeutics, Inc. (hereafter, “Transposon”) for OBP601 which was announced in a press release “Announcement of License Agreement for Nucleotide Reverse Transcriptase Inhibitor OBP-601 (Censavudine)”. This License Agreement is an exclusive worldwide license, with sublicensing rights, for OBP-601, and the total amount of the License Agreement is in excess of $ 300 million. Transposon is conducting development of OBP-601 for the treatment of life-threatening and debilitating diseases.
A gradual increase in the interest of the researchers towards oncolytic virus therapy will develop the market which will eventually bring complete revolution in terms of applications to the cancer patients. Also this report showed how major competitors are developing new therapy on oncolytics virus which increases the market in further years.
Based on the products, the market is divided into Adenoviruses, Herpes Simplex Virus, Vesicular Stomatis Virus, Vaccinia Virus and Newcastle Disease Virus. Based on Application, the market is bifurcated into Melanoma, Lung Cancer, Breast Cancer, and Others. Based on Type, the market is bifurcated into Monoclonal Antibodies, Cancer Vaccines, Checkpoint Inhibitors, and Immunomodulators. Based on End User, the market is bifurcated into Hospitals, Specialty Clinics, and Cancer Research Institutes. On the basis of regional analysis, the Global Q Market is classified into North America, Europe, Asia Pacific, and Rest of the world. North America holds the largest market share due to the rising incidence of the disease, increasing ease of access to modern therapeutics, coupled with expanding geriatric population has propelled the oncolytic virus therapy in the region.